Table 3.
Adverse events reported during treatment with chemotherapy plus bevacizumab (grade 3 or higher) according to the Common Terminology Criteria for Adverse Events (version 4.02) of the National Cancer Institute
| Adverse event | Absolute frequency | Relative frequency |
|---|---|---|
| Hematologic | 13 | 35.1% |
| Anemia | 1 | 2.7% |
| Neutropenia | 10 | 27.0% |
| Thrombocytopenia | 5 | 13.5% |
| Thrombocytosis | 1 | 2.7% |
| Nonhematologic | 9 | 24.3% |
| Arterial hypertension | 4 | 10.8% |
| Proteinuria | 0 | 0.0% |
| Hyponatremia | 0 | 0.0% |
| Renal failure | 1 | 2.7% |
| Thromboembolic event | 1 | 2.7% |
| Hemoptysis | 2 | 5.4% |
| Infection | 1 | 2.7% |
| None | 20 | 54.1% |